Despite the ongoing pandemic, Abbott Laboratories Inc. reported revenue growth in all four of its main businesses during the first quarter of 2020, including 2.9% organic year-over-year growth in its medical device businesses and 0.7% growth in diagnostics revenues.
“The underlying fundamentals of our business remain strong and our manufacturing and supply chain have been highly resilient,” Abbott CEO...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?